PASSAGE BIO INC (PASG)
US7027121000 - Common Stock
Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
PHILADELPHIA, April 22, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the...
PASG Stock Earnings: Passage Bio Beats EPS for Q4 2023
PASG stock results show that Passage Bio beat analyst estimates for earnings per share the fourth quarter of 2023.
PASG Stock Earnings: Passage Bio Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Passage Bio (NASDAQ:PASG) just reported results for the fourth quarter of 2023....
Passage Bio Seeks Pennsylvania College Student Candidates for Third Annual Tachi Yamada Scholarship Program
$10,000 scholarship to be awarded to a rising junior with a life science major attending a Pennsylvania-based four-year college or university Scholarship...
Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights
Continued momentum in upliFT-D trial of PBFT02 for the treatment of patients with frontotemporal dementia (FTD) with granulin mutations (GRN) with clinical...
Passage Bio to Participate in Upcoming Investor Conferences
Passage Bio to Participate in Upcoming Investor Conferences
PHILADELPHIA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the...
7 Analyst-Backed Stocks With Promising 10-Bagger Potential
Although true 10-baggers are by nature extremely difficult to come by, these analyst-backed stocks may offer a decent shot.
Passage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Passage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
PHILADELPHIA, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the...
7 Nano-Cap Stocks That Pack a Serious Punch for Their Weight
Although nano-cap stocks are super-risky just like stealing bases in baseball, there may be a time and place for extreme speculation.
Passage Bio stock climbs 9% on dementia study, program update (NASDAQ:PASG)
Passage Bio (PASG) shares surged 9% on encouraging Phase 1/2 data for gene therapy candidate PBFT02 in treating FTD-GRN, a type of early onset dementia. Read more here.
Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities
Dose 1 of PBFT02 achieved supraphysiologic CSF progranulin levels in each of the first three treated patients at 30 days after treatmentElevated...
Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
PHILADELPHIA, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing...
Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights
Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights
On track to present initial safety and biomarker data from three Cohort 1 patients in global Phase 1/2 upliFT-D trial of PBFT02 for the treatment of...
Passage Bio to Present at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology Conference
Passage Bio to Present at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology Conference
PHILADELPHIA, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing...
Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PHILADELPHIA, Oct. 20, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing...
Passage Bio to Present at Chardan’s 7th Annual Genetic Medicines Conference
Passage Bio to Present at Chardan’s 7th Annual Genetic Medicines Conference
PHILADELPHIA, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing...
Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business Highlights
Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business Highlights
Reported promising interim data from Cohorts 1-4 in the Imagine-1 clinical trial for GM1 gangliosidosis (GM1); PBGM01 continued to have a favorable safety...
Passage Bio Announces Promising Interim Clinical Data from First Eight Patients with GM1 Gangliosidosis in Imagine-1 Study
Interim safety data up to 28 months showed Dose 1 and 2 of PBGM01 were well tolerated and had a favorable safety and immunological profileDose 2 resulted...